Prognostic implications of differences in forced vital capacity in black and white US adults: Findings from NHANES III with long-term mortality follow-up.
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
22
03
2021
revised:
22
07
2021
accepted:
23
07
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
epublish
Résumé
Because Forced Vital Capacity (FVC) is reduced in Black relative to White Americans of the same age, sex, and height, standard lung function prediction equations assign a lower "normal" range for Black patients. The prognostic implications of this race correction are uncertain. We analyzed 5,294 White and 3,743 Black participants age 20-80 in NHANES III, a nationally-representative US survey conducted 1988-94, which we linked to the National Death Index to assess mortality through December 31, 2015. We calculated the FVC-percent predicted among Black and White participants, first applying NHANES III White prediction equations to all persons, and then using standard race-specific prediction equations. We used Cox proportional hazard models to calculate the association between race and all-cause mortality without and with adjustment for FVC (using each FVC metric), smoking, socioeconomic factors, and comorbidities. Black participants' age- and sex-adjusted mortality was greater than White participants (HR 1.46; 95%CI:1.29, 1.65). With adjustment for FVC in liters (mean 3.7 L for Black participants, 4.3 L for White participants) or FVC percent-predicted using White equations for everyone, Black race was no longer independently predictive of higher mortality (HR∼1.0). When FVC-percent predicted was "corrected" for race, Black individuals again showed increased mortality hazard. Deaths attributed to chronic respiratory disease were infrequent for both Black and White individuals. Lower FVC in Black people is associated with elevated risk of all-cause mortality, challenging the standard assumption about race-based normal limits. Black-White disparities in FVC may reflect deleterious social/environmental exposures, not innate differences. No funding.
Sections du résumé
BACKGROUND
BACKGROUND
Because Forced Vital Capacity (FVC) is reduced in Black relative to White Americans of the same age, sex, and height, standard lung function prediction equations assign a lower "normal" range for Black patients. The prognostic implications of this race correction are uncertain.
METHODS
METHODS
We analyzed 5,294 White and 3,743 Black participants age 20-80 in NHANES III, a nationally-representative US survey conducted 1988-94, which we linked to the National Death Index to assess mortality through December 31, 2015. We calculated the FVC-percent predicted among Black and White participants, first applying NHANES III White prediction equations to all persons, and then using standard race-specific prediction equations. We used Cox proportional hazard models to calculate the association between race and all-cause mortality without and with adjustment for FVC (using each FVC metric), smoking, socioeconomic factors, and comorbidities.
FINDINGS
RESULTS
Black participants' age- and sex-adjusted mortality was greater than White participants (HR 1.46; 95%CI:1.29, 1.65). With adjustment for FVC in liters (mean 3.7 L for Black participants, 4.3 L for White participants) or FVC percent-predicted using White equations for everyone, Black race was no longer independently predictive of higher mortality (HR∼1.0). When FVC-percent predicted was "corrected" for race, Black individuals again showed increased mortality hazard. Deaths attributed to chronic respiratory disease were infrequent for both Black and White individuals.
INTERPRETATION
CONCLUSIONS
Lower FVC in Black people is associated with elevated risk of all-cause mortality, challenging the standard assumption about race-based normal limits. Black-White disparities in FVC may reflect deleterious social/environmental exposures, not innate differences.
FUNDING
BACKGROUND
No funding.
Identifiants
pubmed: 34458707
doi: 10.1016/j.eclinm.2021.101073
pii: S2589-5370(21)00353-9
pmc: PMC8379634
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101073Informations de copyright
© 2021 The Authors.
Références
Eur Respir J. 2015 Jan;45(1):38-50
pubmed: 25193994
Vital Health Stat 2. 1992 Sep;(113):1-35
pubmed: 1413563
N Engl J Med. 2021 Feb 4;384(5):396-399
pubmed: 33406354
Eur Respir J. 2013 Jun;41(6):1249-51
pubmed: 23728403
Int J Tuberc Lung Dis. 2013 Mar;17(3):400-5
pubmed: 23407230
Eur Respir J. 2010 Nov;36(5):1002-6
pubmed: 20562119
S Afr Med J. 1986 Aug 30;70(5):270-4
pubmed: 3529452
J Heart Lung Transplant. 2015 Jan;34(1):1-15
pubmed: 25085497
J Occup Environ Med. 2014 Oct;56 Suppl 10:S23-9
pubmed: 25285971
JAMA Intern Med. 2021 Jul 1;181(7):968-976
pubmed: 34047754
Int J Environ Res Public Health. 2011 Jun;8(6):1755-71
pubmed: 21776200
Chest. 2021 Jun;159(6):2173-2182
pubmed: 33497651
S Afr Med J. 1984 May 12;65(19):768-72
pubmed: 6372134
Health Aff (Millwood). 2005 Mar-Apr;24(2):343-52
pubmed: 15757918
Respir Med. 1995 Apr;89(4):312-3
pubmed: 7597276
Epidemiology. 2008 Sep;19(5):690-701
pubmed: 18703932
Environ Health Perspect. 2012 Dec;120(12):1699-704
pubmed: 22889745
Am J Public Health. 2015 Jun;105(6):1269-75
pubmed: 25320897
Am J Respir Crit Care Med. 2001 Nov 1;164(9):1647-54
pubmed: 11719304
BMJ Open. 2019 Jun 20;9(6):e027528
pubmed: 31227536
Thorax. 2014 May;69(5):465-73
pubmed: 24353008
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Int J Epidemiol. 2012 Jun;41(3):782-90
pubmed: 22434864
Chest. 2018 Feb;153(2):427-437
pubmed: 29017956
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1463-1472
pubmed: 29192835
Thorax. 2003 May;58(5):388-93
pubmed: 12728157
Int J Tuberc Lung Dis. 2013 Apr;17(4):568
pubmed: 23485392
Int J Epidemiol. 2002 Apr;31(2):383-90
pubmed: 11980800
Thorax. 2011 Jan;66(1):49-54
pubmed: 20980245
Int J Tuberc Lung Dis. 2013 Mar;17(3):288
pubmed: 23407218
J Epidemiol Community Health. 2011 Jan;65(1):26-34
pubmed: 19854747
Eur Respir J. 2013 Jun;41(6):1362-70
pubmed: 22878881
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Pediatrics. 2010 Aug;126(2):204-13
pubmed: 20643717
N Engl J Med. 2010 Jul 22;363(4):321-30
pubmed: 20647190
N Engl J Med. 2020 Aug 27;383(9):874-882
pubmed: 32853499
Vital Health Stat 1. 1994 Jul;(32):1-407
pubmed: 7975354
BMC Public Health. 2016 Feb 01;16:96
pubmed: 26832923
Chest. 2015 Mar;147(3):792-797
pubmed: 25254426
N Engl J Med. 2007 Dec 6;357(23):2338-47
pubmed: 18057336
Pneumonia (Nathan). 2015 Dec 1;6:101-114
pubmed: 31641584
Eur Respir J. 2010 Sep;36(3):480-7
pubmed: 20150201
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Chest. 2007 Nov;132(5):1608-14
pubmed: 17998360
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1575-1577
pubmed: 30917289
Int J Epidemiol. 2012 Oct;41(5):1490; author reply 1491-2
pubmed: 23045209
N Engl J Med. 2010 Jul 22;363(4):385-6
pubmed: 20647189
Am J Respir Crit Care Med. 2011 Sep 1;184(5):521-7
pubmed: 21562132
JAMA. 2019 Jul 9;322(2):113-114
pubmed: 31169890
Am J Epidemiol. 2004 Nov 1;160(9):893-900
pubmed: 15496542